Last reviewed · How we verify
XF-73
At a glance
| Generic name | XF-73 |
|---|---|
| Also known as | Exeporfinium chloride |
| Sponsor | Destiny Pharma Plc |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection (PHASE2)
- Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects (PHASE1, PHASE2)
- Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XF-73 CI brief — competitive landscape report
- XF-73 updates RSS · CI watch RSS
- Destiny Pharma Plc portfolio CI